282 related articles for article (PubMed ID: 6699409)
21. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
Phillips NC; Tsao MS
Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
[TBL] [Abstract][Full Text] [Related]
23. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
24. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.
Schroit AJ; Fidler IJ
Cancer Res; 1982 Jan; 42(1):161-7. PubMed ID: 7053846
[TBL] [Abstract][Full Text] [Related]
25. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
26. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.
Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ
J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661
[TBL] [Abstract][Full Text] [Related]
27. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues.
Lopez-Berestein G; Mehta K; Mehta R; Juliano RL; Hersh EM
J Immunol; 1983 Apr; 130(4):1500-2. PubMed ID: 6300230
[No Abstract] [Full Text] [Related]
28. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
29. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
Talmadge JE; Schneider M; Collins M; Phillips H; Herberman RB; Wiltrout RH
J Immunol; 1985 Aug; 135(2):1477-83. PubMed ID: 4008928
[TBL] [Abstract][Full Text] [Related]
30. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
32. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.
Sone S; Utsugi T; Tandon P; Yanagawa H; Okubo A; Ogura T
Cancer Immunol Immunother; 1990; 30(6):357-62. PubMed ID: 2302725
[TBL] [Abstract][Full Text] [Related]
33. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
Reisser D; Jeannin JF; Martin F
C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063
[TBL] [Abstract][Full Text] [Related]
34. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
35. Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes.
Sone S; Tandon P; Utsugi T; Ogawara M; Shimizu E; Nii A; Ogura T
Int J Cancer; 1986 Oct; 38(4):495-500. PubMed ID: 3093390
[TBL] [Abstract][Full Text] [Related]
36. The incubation of human blood monocytes with tumor necrosis factor-alpha leads to lysis of tumor necrosis factor-sensitive but not resistant tumor cells.
Nii A; Fidler IJ
Lymphokine Res; 1990; 9(2):113-24. PubMed ID: 2338840
[TBL] [Abstract][Full Text] [Related]
37. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes.
Mehta K; Lopez-Berestein G; Hersh EM; Juliano RL
J Reticuloendothel Soc; 1982 Aug; 32(2):155-64. PubMed ID: 7161762
[TBL] [Abstract][Full Text] [Related]
38. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
39. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
40. Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response.
Pabst MJ; Hedegaard HB; Johnston RB
J Immunol; 1982 Jan; 128(1):123-8. PubMed ID: 6274954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
